Botulinum toxin (A & B)
- TRADE NAME: Azzalure (Galderma); Bocouture (Merz); Botox (Allergan); Dysport (Ipsen); Myobloc (Solstice); Neurobloc (Eisai); Vistabel (Allergan); Xeomin (Merz)
- INDICATIONS: Blepharospasm, hemifacial spasm, spasmodic torticollis, sialorrhea, hyperhidrosis, strabismus, oromandibular dystonia, cervical dystonia, spasmodic dysphonia, chronic migraine; urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have overactivity of the bladder; cosmetic application for wrinkles
- CLASS: Acetylcholine inhibitor, Neuromuscular blocker, Ophthalmic agent, toxin
- HALF-LIFE: 3–6 months
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminoglycosides, Anticholinergics, Tiotropium, Trospium
PREGNANCY CATEGORY: C
Distant spread of toxin effect - postmarketing reports indicate that all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing diffculties. These symptoms have been reported hours to weeks after injection.
An antitoxin is available in the event of overdose or misinjection.
Please login to see the rest of this drug profile
SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
GENITOURINARY
OTIC
OCULAR
LOCAL
OTHER
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric